Search Results

San Francisco, CA and Boston, MA, May 27, 2026 (Globe Newswire) -- Apogee Therapeutics has entered a strategic financing collaboration with Blackstone Life Sciences valued at $1.3 billion. The agreement will support Phase 3 development and potential commercialization of its immunology candidate zumilokibart. The funding is intended to accelerate late-stage clinical progress and prepare the program for possible market launch. Read full article here.

Springdale, AR, May 28, 2026 (PR Newswire) -- NOWDiagnostics has appointed Lisa Nibauer as its new chief executive officer. The leadership change is intended to guide the company’s next phase of innovation and organizational transformation. NOWDiagnostics aims to accelerate development and commercialization of its diagnostic technologies under the new leadership. Read full article here.

South San Francisco, CA, June 2, 2026 (NewLimit) -- NewLimit has secured $435 million in funding in a round led by Founders Fund to accelerate development of its longevity-focused platform. The capital will support advancement of programs aimed at reprogramming cells to address age-related diseases. The financing is expected to expand research capabilities and advance the company’s long-term therapeutic pipeline. Read full article here.

Exton, PA, June 1, 2026 (PR Newswire) -- West Pharmaceutical Services has appointed Michel Lagarde as its new president and chief executive officer. The leadership transition is intended to guide the company’s strategic direction and operational execution. West aims to continue expanding its global pharmaceutical packaging and delivery systems business under new leadership. Read full article here.

Boulder, CO, June 1, 2026 (PR Newswire) -- Edgewise Therapeutics has agreed to divest its Sevasemten asset in a transaction valued at up to $2.65 billion. The deal is designed to strengthen the company’s financial position and streamline its strategic focus on cardiovascular drug development. Following the sale, Edgewise plans to concentrate resources on advancing its heart-related therapeutic pipeline. Read full article here.

Cambridge, MA, May 14, 2026 (PR Newswire) -- Create Medicines has secured $122 million in Series B financing to accelerate development of its in vivo CAR-based therapeutic programs. The funding will support pipeline expansion across autoimmune disease and oncology indications. The investment is intended to advance the company’s platform toward clinical-stage development. Read full article here.

Franklin Lakes, NJ, May 18, 2026 (BD) -- BD has appointed Peter Menziuso as executive vice president and president of its BD Interventional segment. The leadership change is intended to support the company’s strategic priorities and strengthen its interventional business operations. The appointment aligns with BD’s efforts to drive growth and expand innovation across its medical technology portfolio. Read full article here.

South San Francisco, CA, May 18, 2026 (Globe Newswire) -- Quince Therapeutics has announced the acquisition of OrphAI alongside a private financing arrangement valued at up to $187 million. The transaction is designed to support advancement of the company’s pulmonary disease pipeline and broaden its development capabilities. The funding is expected to provide additional resources for clinical progress and future growth initiatives. Read full article here.

Malvern, PA, May 20, 2026 (MyChesCo) -- LifeScan has named Jonathan Salkin as its new chief executive officer as part of a leadership transition. The appointment is intended to support the company’s strategic direction and continued business development efforts. LifeScan aims to strengthen its position in diabetes management solutions under the new leadership structure. Read full article here.

Cambridge, MA, May 15, 2026 (Yahoo Finance) -- Biogen has completed its $5.3 billion acquisition of Apellis Pharmaceuticals. The deal strengthens Biogen’s presence in rare disease and complement-mediated disorder therapies. The company is expected to integrate Apellis’s portfolio into its broader neurology and specialty medicine strategy. Read full article here.

Brussels, Belgium, May 3, 2026 (UCB) -- UCB has announced plans to acquire Candid Therapeutics to strengthen its immunology pipeline. The transaction will add novel T-cell engager therapies aimed at addressing complex immune-mediated diseases. The deal is intended to broaden UCB’s research capabilities and support development of next-generation biologic treatments. Read full article here.

Humlebaek, Denmark, March 4, 2026 (Coloplast) -- Coloplast has appointed Gavin Wood as its new chief executive officer. The leadership transition is aimed at supporting the company’s long-term strategic and commercial objectives. Coloplast expects the appointment to help drive continued growth across its medical care and device businesses. Read full article here.